A placebo controlled double blind trial (QuANTUM-FIRST) investigating quizartinib combined with IC for newly diagnosed FLT3-ITD positive AML is ongoing (NCT02668653) (Table 1). The gene discussed is FLT3; the disease is acute myeloid leukemia.